Busy clinicians recognise that a broad spectrum of clinical features is associated with antiphospholipid antibodies (aPL). However, it is sometimes difficult to be clear as to the links between clinical syndromes and positive or negative blood tests.
The concept of ‘sero-negative APS’ has evolved and there is now abundant evidence to suggest that such patients exist – not least the fact that treatment of these patients is very often successful.
The problem currently being assessed is that present tests for Hughes Syndrome (anticardiolipin, lupus anticoagulant and (occasionally) ß2 GP1) are less than perfect.
This presentation will highlight the problems and offer some (compromise) solutions.
Upon completion of this session, participants should be able to:
- discuss the spectrum of antiphospholipid syndrome
- identify the diagnostic utility of antiphospholipid antibody tests
- describe the controversial aspects of primary and secondary thrombosis prevention in antiphospholipid syndrome
- discuss the management of catastrophic antiphospholipid syndrome patients
To see other sessions for this day, use the date buttons to the left.